[go: up one dir, main page]

WO2019116351A3 - Compositions and methods for treating and preventing a staphylococcal infection - Google Patents

Compositions and methods for treating and preventing a staphylococcal infection Download PDF

Info

Publication number
WO2019116351A3
WO2019116351A3 PCT/IB2018/060141 IB2018060141W WO2019116351A3 WO 2019116351 A3 WO2019116351 A3 WO 2019116351A3 IB 2018060141 W IB2018060141 W IB 2018060141W WO 2019116351 A3 WO2019116351 A3 WO 2019116351A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating
preventing
staphylococcal infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/060141
Other languages
French (fr)
Other versions
WO2019116351A2 (en
Inventor
Joshua Costin
John Williams
Dan Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hsrx Group LLC
Original Assignee
Hsrx Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsrx Group LLC filed Critical Hsrx Group LLC
Publication of WO2019116351A2 publication Critical patent/WO2019116351A2/en
Publication of WO2019116351A3 publication Critical patent/WO2019116351A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates generally to treatment regimes, compositions, and methods of use to treat and/or prevent a Staphylococcal infection. The compositions can contain compounds found in green tea.
PCT/IB2018/060141 2017-12-14 2018-12-14 Compositions and methods for treating and preventing a staphylococcal infection Ceased WO2019116351A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762598759P 2017-12-14 2017-12-14
US62/598,759 2017-12-14

Publications (2)

Publication Number Publication Date
WO2019116351A2 WO2019116351A2 (en) 2019-06-20
WO2019116351A3 true WO2019116351A3 (en) 2019-08-29

Family

ID=66819753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/060141 Ceased WO2019116351A2 (en) 2017-12-14 2018-12-14 Compositions and methods for treating and preventing a staphylococcal infection

Country Status (1)

Country Link
WO (1) WO2019116351A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268009B1 (en) * 1996-02-26 2001-07-31 The Procter & Gamble Company Green tea extract subjected to cation exchange treatment and nanofiltration to improve clarity and color
US20060172012A1 (en) * 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20060286181A1 (en) * 2005-06-17 2006-12-21 Gardiner Paul T Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism
US20150044306A1 (en) * 2013-08-12 2015-02-12 Melvin Mitchell Process for fractionation and extraction of herbal plant material to isolate extractives for pharmaceuticals and nutraceuticals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268009B1 (en) * 1996-02-26 2001-07-31 The Procter & Gamble Company Green tea extract subjected to cation exchange treatment and nanofiltration to improve clarity and color
US20060172012A1 (en) * 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
US20060286181A1 (en) * 2005-06-17 2006-12-21 Gardiner Paul T Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism
US20150044306A1 (en) * 2013-08-12 2015-02-12 Melvin Mitchell Process for fractionation and extraction of herbal plant material to isolate extractives for pharmaceuticals and nutraceuticals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARAKAS ET AL.: "Antibacterial and antitumor activities of melatonin", vol. 3, no. 2, January 2013 (2013-01-01), pages 33 - 39, XP0055632735 *

Also Published As

Publication number Publication date
WO2019116351A2 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
ZA201907052B (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
JOP20210060A1 (en) Modulators of alpha-1 antitrypsin
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
EP4599890A3 (en) Sunitinib for preventing and/or treating amyotrophic lateral sclerosis
MX2017012545A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
MX2016009248A (en) Nitrogen containing compounds and their use as antibacterial agents.
MX363678B (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections.
PH12022550130A1 (en) Enzyme inhibitors
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
HK1258276A1 (en) Compounds and combinations for the treatment of hiv
AU2017277478A1 (en) Pharmaceutical combinations for treating cancer
MX2017012535A (en) Novel heterocyclic compounds and their use in preventing or treating bacterial infections.
SA522431538B1 (en) Methods and Compositions for the Treatment of Hair Loss
PH12022550118A1 (en) Enzyme inhibitors
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
MX2017014080A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
WO2019098811A3 (en) Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp)
MX2022006229A (en) Compositions and methods for treatment of insulin resistance.
MX2017012539A (en) Heterocyclic compounds and their use in preventing or treating bacterial infections.
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
WO2019116351A3 (en) Compositions and methods for treating and preventing a staphylococcal infection
WO2019070709A8 (en) Compounds for treating or preventing flavivirus infections
MX2020012805A (en) Compounds for pain treatment, compositions comprising same, and methods of using same.
MY201019A (en) Composition and Combined Medication Method for Treating Enterovirus Infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18887663

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18887663

Country of ref document: EP

Kind code of ref document: A2